Participants lost to follow-up, n (%)
|
33 (10.3)
|
14 (12.5)
|
14 (13.5)
|
5 (4.8)
|
15 (14.3)
|
Treatment failure, n (%)
|
Early
|
0 (0)
|
0 (0)
|
0 (0)
|
0 (0)
|
0 (0)
|
Late*
|
70 (24.3)
|
22 (22.5)
|
30 (33.3)
|
18 (18)
|
2 (2.2)
|
Day of failure, median (range)
|
21 (14, 28)
|
24.5 (14, 28)
|
21 (14, 28)
|
21 (14, 28)
|
17.5 (14, 21)
|
Reinfection*
|
68 (23.6)
|
22 (22.5)
|
30 (33.3)
|
16 (16)
|
1 (1.1)
|
Recrudescence
|
2 (0.7)
|
0 (0)
|
0 (0)
|
2 (2)
|
1 (1.1)
|
Day 3 clearance, % (95 % CI)a
|
99.7 (97.5–100)
|
99.1 (94.5–100)
|
100 (96.5–100)
|
100 (96.6–100)
|
100 (96.6–100)
|
ACPR, % (95 % CI)b
|
Uncorrected
|
75.7 (70–80.5)
|
77.6 (68–83.4)
|
67.7 (56–76.3)
|
82 (73.1–89)
|
97.8 (92.2–99.7)
|
PCR-corrected
|
99.3 (97.5–99.9)
|
100 (96.3–100)
|
100 (96–100)
|
98 (93–100)
|
99 (94–100)
|
Kaplan–Meier survival rate on day 28, % (95 % CI)c
|
Uncorrected
|
76.3 (71.4–81.2)
|
78.2 (70.2–86.3)
|
67.4 (58–77.1)
|
82.2 (74.8–89.7)
|
97.9 (95–100)
|
PCR-corrected
|
99.3 (98.3–100)
|
100d
|
100d
|
97.9 (94.9–100)
|
99.0 (96.9–100)
|